Abbott Laboratories - Company Profile
Powered by 
All the sales intelligence you need on Abbott Laboratories in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Abbott Laboratories fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Abbott Laboratories.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Abbott Laboratories (Abbott) is a medical devices and health care company that discovers, develops, manufactures, and sells products. It primarily offers gastroenterology products, women’s health products, cardiovascular and metabolic products, pain and central nervous system products, respiratory drugs and vaccines, biosimilar products, core laboratory and transfusion medicine systems, point-of-care systems, rapid diagnostics lateral flow testing products, informatics and automation solutions, nutritional products, rhythm management products, electrophysiology products, heart failure related products, vascular products, structural heart products, neuromodulation products, among others. The company offers its products to customers through wholesalers, distributors, government agencies, healthcare facilities, pharmacies, and independent retailers in North America, Latin America, the Middle East, Europe, Asia-Pacific, and Africa. Abbott is headquartered in Abbott Park, Illinois, the US.
Headquarters
United States of America
Address
100 Abbott Park Road, Abbot Park, Illinois, 60064-3500
Website
www.abbott.com
Telephone
1 224 6676100
No of Employees
115,000
Industry
Medical Equipment
Ticker Symbol & Exchange
ABT (NYSE)
Revenue (2024)
$44.3B
5.7%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-51.3%
(2024 vs 2023)
Market Cap*
$158.1B
Net Profit Margin (2024)
XYZ
-53.9%
(2024 vs 2023)
* As of and is in US$
Abbott Laboratories premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Established Pharmaceutical | Acculink |
| Gastroenterology Products | FreeStyle |
| Women’s Health Products | Accunet |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In June, the company expanded its partnership with MiniMed to commercialize dual glucose-ketone sensors designed to combine exclusively with MiniMed smart dosing systems. |
| 2026 | New Products/Services | In May, the company launched Ensure Strength Pro in India. |
| 2026 | Regulatory Approval | In April, the company received US FDA clearance and CE mark for next-generation Ultreon 3.0 AI-powered coronary imaging platform. |
Competitor Comparison
| Key Parameters | Abbott Laboratories | Johnson & Johnson | Eli Lilly and Co | Merck & Co Inc | Pfizer Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Abbott | New Brunswick | Indianapolis | Rahway | New York City |
| State/Province | Illinois | New Jersey | Indiana | New Jersey | New York |
| No. of Employees | 115,000 | 138,200 | 50,605 | 75,000 | 75,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Robert B. Ford | Chief Executive Officer; Chairman | Executive Board | 2021 | 52 |
| Philip P. Boudreau | Executive Vice President - Finance; Chief Financial Officer | Senior Management | 2024 | 53 |
| Sabina Ewing | Chief Information Officer; Senior Vice President - Business and Technology Services | Senior Management | - | - |
| Uri Yaron | Senior Vice President - Electrophysiology | Senior Management | 2023 | - |
| Fernando Mateus | Senior Vice President - International Nutrition | Senior Management | 2021 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer